Zacks Upgrades BIOLASE to Neutral (BIOL)
BIOLASE (NASDAQ:BIOL) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, AnalystRatings.Net reports. The firm currently has a $2.00 target price on the stock. Zacks‘ price target would indicate a potential upside of 5.82% from the company’s current price.
BIOLASE (NASDAQ:BIOL) traded down 2.58% on Tuesday, hitting $1.89. 149,893 shares of the company’s stock traded hands. BIOLASE has a one year low of $1.1554 and a one year high of $6.0019. The stock’s 50-day moving average is $1.88 and its 200-day moving average is $3.52. The company’s market cap is $64.5 million.
BIOLASE (NASDAQ:BIOL) last released its earnings data on Wednesday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.04) by $0.02. The company had revenue of $14.20 million for the quarter, compared to the consensus estimate of $15.69 million. BIOLASE’s revenue was up 16.4% compared to the same quarter last year. On average, analysts predict that BIOLASE will post $-0.21 earnings per share for the current fiscal year.
A number of other firms have also recently commented on BIOL. Analysts at Sidoti upgraded shares of BIOLASE from a “neutral” rating to a “buy” rating in a research note to investors on Thursday, September 12th. Analysts at WallachBeth Capital cut their price target on shares of BIOLASE from $6.50 to $4.50 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $4.75.
BIOLASE, Inc, formerly BIOLASE Technology, Inc is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.